Ipsilateral breast tumour recurrence was the first treatment failure for 354 patients ( 13 % ) in the no boost group versus 237 patients ( 9 % ) in the boost group , HR 0.65 ( 99 % CI 0.52-0 .81 , p < 0.0001 ) .